Recombinant Influenza A HA (A/California/07/2009(H1N1))

Influenza viruses are members of the Orthomyxoviridae family and are phylogenetically grouped into four genera: A, B, C and D¹. Influenza A viruses have two surface glycoproteins, hemagglutinin (HA) and neuraminidase (NA), with HA outnumbering NA by five- to 10-fold. Based on HA antigenicity, influenza A viruses are divided into 18 known subtypes (H1-H18), and the HA subtypes are further divided into group 1 (H1, H2, H5, H6, H8, H9, H11, H12, H13, H16, H17, and H18) and group 2 (H3, H4, H7, H10, H14, and H15).
HA is a homotrimer consisting of a globular head domain atop a membrane-proximal stem domain¹. The globular head domain of H1-H16 viruses has a membrane-distal receptor binding site that binds to sialylated glycan receptors on host cells to initiate viral entry. H17 and H18, found only in bats, instead use the major histocompatibility complex class II molecule as host receptor. HA mediates virus-host membrane fusion in a pH dependent process that occurs in the endosome.
Influenza annually infects 10 to 20% of the human population causing severe illness and death². HA is constantly evolving to escape herd immunity and vaccine preparations¹. The globular head domain is immunodominant with high plasticity, while the immunosubdominant stalk domain is relatively conserved². Aquatic birds are the primary reservoir for influenza A¹. Reassortment with human and swine viruses can result in new pandemic strains. Broadly neutralizing antibodies that target relatively conserved HA domains and neutralize multiple strains are being studied¹.
HA can be used to rapidly quantify influenza virus using the hemagglutination assay, which takes advantage of HA’s ability to agglutinate red blood cells¹. HA can also be used in the hemagglutination inhibition assay to measure the virus-neutralizing capacity of antibodies and sera. Additionally, HA is commonly used in laboratories for protein purification and labeling as an HA-tag, a linear epitope consisting of nine amino acids.

Viral

ELISA binding

ACP41953.1

DTLCIGYHANNSTDTVDTVLEKNVTVTHSVNLLEDKHNGKLCKLRGVAPLHLGKCNIAGWILGNPECESLSTASSWSYIVETPSSDNGTCYPGDFIDYEELREQLSSVSSFERFEIFPKTSSWPNHDSNKGVTAACPHAGAKSFYKNLIWLVKKGNSYPKLSKSYINDKGKEVLVLWGIHHPSTSADQQSLYQNADAYVFVGSSRYSKKFKPEIAIRPKVRDQEGRMNYYWTLVEPGDKITFEATGNLVVPRYAFAMERNAGSGIIISDTPVHDCNTTCQTPKGAINTSLPFQNIHPITIGKCPKYVKSTKLRLATGLRNIPSIQSRGLFGAIAGFIEGGWTGMVDGWYGYHHQNEQGSGYAADLKSTQNAIDEITNKVNSVIEKMNTQFTAVGKEFNHLEKRIENLNKKVDDGFLDIWTYNAELLVLLENERTLDYHDSNVKNLYEKVRSQLKNNAKEIGNGCFEFYHKCDNTCMESVKNGTYDYPKYSEEAKLNREEIDGVKLESTRIYQ

Lyophilized

63 kDa

63 kDa

Lyophilized powder from 0.01M Phosphate Buffered Saline (150mM NaCI) (PBS) pH 7.4, with 5% Trehalose

Reconstitute at 0.1-1 mg/ml using filtered PBS. Gently mix by vortexing and/or inversion until fully dissolved. Centrifuge if necessary.

This lyophilized protein is stable for twelve months when stored at -20°C to -70°C. After aseptic reconstitution, this protein may be stored for one month at 2°C to 8°C or for three months at -20°C to -70°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles.

Ambient

Ligand

Viral

Research Use Only

C3W5X2

1. Wu NC, Wilson IA. Cold Spring Harb Perspect Med. 10(8):a038778. 2020.
2. Kirkpatrick E, Qiu X, Wilson PC, et al. Sci Rep. 8(1):10432. 2018.